Northsea Therapeutics
4 known investors
NorthSea Therapeutics is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as oral treatments for metabolic, cholestatic, and fibrotic diseases. Its pipeline targets conditions such as intestinal failure-associated liver disease, severe hypertriglyceridemia, and metabolic dysfunction-associated steatohepatitis.
Investors · 4
Frequently asked questions
- What does Northsea Therapeutics do?
- NorthSea Therapeutics is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as oral treatments for metabolic, cholestatic, and fibrotic diseases. Its pipeline targets conditions such as intestinal failure-associated liver disease, severe hypertriglyceridemia, and metabolic dysfunction-associated steatohepatitis.
- Who are Northsea Therapeutics's investors?
- Northsea Therapeutics's investors include New Science Ventures, venBio Partners, Ysios Capital, Sofinnova Ventures.